CD38 Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma

Multiple myeloma remains an incurable disease. CD38 is a desirable target for therapeutic antibodies, including isatuximab and daratumumab. Nurse practitioners working in the oncology setting play an essential role in the management and education of patients receiving these therapies. This article provides a practical overview of anti-CD38 antibodies for oncology nurse practitioners, including infusion reaction mitigation, laboratory interpretation, and clinical decision making.